Janus Global Life Sciences Fund (JAGLX)
Sector Experts Seeking Growth and Innovation in Health Care

SHARE CLASS

FUND FACTS (JAGLX)

Inception Date12/31/1998
NAV (As of 3/4/15 )$58.31
Total Net Assets (As of 1/31/15)$3.63B
Annual Expense Ratio
(As of fiscal year end 9/30/14)
GROSS 0.93%
NET 0.93%

Performance (As of 12/31/14)
1 Year34.83%
3 Year37.82%
5 Year24.85%
10 Year13.84%
Morningstar (As of 1/31/15)
CategoryHealth
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

119 Funds Rated
Equity
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Straight Talk

Chapter 1 (1 of 3)

Health Care Investing

Portfolio Manager Andy Acker explains why rapid innovation and changing demographics make health care investing attractive

Chapter 2 (2 of 3)

2014 Lipper Awards

Dedicated analysts and deep fundamental research contribute to the Fund’s 2014 Lipper recognition

Chapter 3 (3 of 3)

Market Insights

Andy Acker discusses what opportunities he’s seeing in the health care sector

Quarterly Commentary - Q4 2014

EXECUTIVE SUMMARY

Strong returns in managed health care led to gains for the sector, while broader indices rose in the fourth quarter.

Our selection of biotechnology stocks drove the Fund’s relative performance.

OvaScience, Celgene and NPS Pharmaceuticals led our individual contributors.

In many cases, stock gains have been driven by fundamental improvements, such as profit growth, innovative drugs advancing and more insured patients gaining access to health care.

FUND MANAGEMENT

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996